Annual Information Update

RNS Number : 2185U

Hikma Pharmaceuticals Plc

12 May 2008

 

Annual Information Update

LONDON, 12 May 2008. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ('Hikma' or 'the Company') (LSE: HIK and DFX:HIK) sets out below a summary of the information which has been published or made available to the public over the previous 12 months. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the London Stock Exchange website (www.londonstockexchange.com/marketnews) or from the press releases page on the Company's website at (http://investors.hikma.com/hikma/regulatorynews.jsp). The Stock Exchange announcements made during the defined period are:

Date of announcement	Headline of announcement
30 Apr 08	LTIP Awards
16 Apr 08	Director/PDMR Shareholding
15 Apr 08	Notice of Annual Report
11 Apr 08	Block listing - Six monthly review
04 Apr 08	Voting Rights and Capital
31 Mar 08	Director/PDMR Shareholding
18 Mar 08	Preliminary Results
04 Mar 08	Voting Rights and Capital
07 Feb 08	Voting Rights and Capital
21 Jan 08	Notification of Transaction
17 Jan 08	Result of Equity Issue
17 Jan 08	Trading Update
17 Jan 08	Issue of Equity
08 Jan 08	Director/PDMR Shareholding
07 Jan 08	Director/PDMR Shareholding
02 Jan 08	Director/PDMR Shareholding
02 Jan 08	Director/PDMR Shareholding
17 Dec 07	Director/PDMR Shareholding
14 Dec 07	Pre-Close Trading Statement
10 Dec 07	Hikma Acquires APM
30 Nov 07	Voting Rights and Capital
21 Nov 07	Update on Lisinopril Contract
31 Oct 07	Legal and General DTR Announcement
15 Oct 07	Director/PDMR Shareholding
08 Oct 07	Conditional Cash Offer
08 Oct 07	Block Listing of Shares
05 Oct 07	Block Listing - 6month Review
19 Sep 07	Option Exercise
14 Sep 07	Director/PDMR Shareholding
11 Sep 07	Notification of Transaction
07 Sep 07	Notification of Transaction
05 Sep 07	Interim Results 2007
09 Aug 07	Hikma Enters Egyptian Market
27 Jun 07	Pre-Close Trading Statement
06 Jun 07	AGM Statement

Any related documents are available at the UKLA's Document Viewing Facility, Financial Services Authority, 25 the North Colonnade, London, E14 5HS. 

All of the above announcements were also made by the Company via the Dubai International Financial Exchange ('DIFX') CANDI system. These announcements may be viewed and downloaded from the DIFX website (www.difx.ae).  

Documents filed with Companies House

The Company submitted filings to Companies House, in relation to the Company's annual return, financial report & accounts, appointments and resignations of directors, allotments of shares and ordinary and special resolutions passed at the Company's 2007 Annual General Meeting. Copies of all these documents can be found on the Companies House website at www.companieshouse.gov.uk or through Companies House Direct at www.direct.companieshouse.gov.uk.

Henry Knowles
Company Secretary
12 May 2008

- ENDS -

Enquiries:

Hikma Pharmaceuticals plc Henry Knowles, Company Secretary Susan Ringdal, Investor Relations Director	[phone]
Brunswick Group LLP Jon Coles / Justine McIlroy / Alex Tweed	[phone]

Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products.  Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.  Hikma's operations are based principally in the Middle East and North Africa ('MENA') region, where it is a market leader and sells across 17 countries, the United States and Europe.  In 2007, the Group achieved revenues of $449 million (2006 $317 million) and profit attributable to shareholders was $63 million (2006 $55 million).  For news and other information, please visit www.hikma.com.

 

END

 

 

AIUZLLFFVEBLBBE